InflaRx Updates Vilobelimab Phase 3 Data After Trial Termination
Ticker: IFRX · Form: 6-K · Filed: Dec 30, 2025 · CIK: 1708688
Sentiment: neutral
Topics: clinical-trial-update, drug-development, data-release
TL;DR
InflaRx dropped a Phase 3 trial for vilobelimab due to futility but is now releasing more data analyses.
AI Summary
On December 30, 2025, InflaRx N.V. provided an update on Phase 3 data analyses for its drug vilobelimab in treating pyoderma gangrenosum. This follows the earlier termination of the trial in 2025 due to futility, as recommended by an Independent Data Monitoring Committee. The company is now outlining multiple data analyses, including the primary intent-to-treat analysis.
Why It Matters
This filing provides crucial post-mortem data analysis for a terminated Phase 3 trial, which could impact investor understanding of the drug's potential and the company's future development strategy.
Risk Assessment
Risk Level: medium — The trial termination due to futility indicates significant clinical development risk, but the release of further data analyses could mitigate or confirm these risks.
Key Players & Entities
- InflaRx N.V. (company) — Registrant
- vilobelimab (drug) — Drug candidate for pyoderma gangrenosum
- pyoderma gangrenosum (disease) — Indication for vilobelimab
- Independent Data Monitoring Committee (organization) — Recommended trial termination
FAQ
What specific data analyses are being disclosed by InflaRx for the vilobelimab Phase 3 study?
The filing states that multiple data analyses are being disclosed, including the primary intent-to-treat analysis.
When did InflaRx announce the termination of the Phase 3 study for vilobelimab?
The filing references a press release issued on December 30, 2025, which provides an update on data analyses following the trial's termination earlier in 2025.
What was the reason for the early termination of the vilobelimab Phase 3 study?
The study was terminated early due to futility, as recommended by an Independent Data Monitoring Committee.
What is the primary indication InflaRx was investigating for vilobelimab?
The primary indication being investigated was pyoderma gangrenosum.
What form type is this filing?
This filing is a Form 6-K, a Report of Foreign Private Issuer.
Filing Stats: 638 words · 3 min read · ~2 pages · Grade level 12.7 · Accepted 2025-12-30 07:57:37
Filing Documents
- ef20062010_6k.htm (6-K) — 12KB
- ef20062010_ex99-1.htm (EX-99.1) — 23KB
- image00001.jpg (GRAPHIC) — 3KB
- image00002.jpg (GRAPHIC) — 24KB
- 0001140361-25-046819.txt ( ) — 74KB
FORWARD-LOOKING STATEMENTS
FORWARD-LOOKING STATEMENTS This Report contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential" or "continue," among others. Forward-looking statements appear in a number of places throughout this Report and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, "Risk factors" and "Cautionary statement regarding forward-looking statements," in our periodic filings with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this Report and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law. EXHIBIT INDEX Exhibit No. Description 99.1 Press Release, dated December 30, 2025
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INFLARX N.V. Date: December 30, 2025 By: /s/ Niels Riedemann Name: Niels Riedemann Title: Chief Executive Officer